KRAS Biomarkers News and reporting on KRAS biomarkers. FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC. Qiagen, Mirati Therapeutics Partner to Develop KRAS Companion Test for NSCLC Drug The tissue-based test will identify cancer patients who may benefit from adagrasib, Mirati's investigational oral small molecule inhibitor of KRAS G12C. Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC As part of its Biomarker Assist program, Amgen will cover the cost of NeoGenomics' KRAS tests for advanced or metastatic NSCLC patients regardless of their insurance status. Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial. Amid COVID-19, Lower Cancer Diagnosis Rates Mean Fewer Patients Getting Molecular Tests, Treatment Premium Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment. Feb 13, 2020 Genetron Health Obtains Regulatory Approval in China for NGS Instrument, Lung Cancer Panel Jan 27, 2020 Colon Cancer Biomarker Undertesting Rates in Real-World Data Points to Precision Oncology Barriers Premium Jan 14, 2020 Qiagen, Amgen Collaborate to Develop CDx for Investigational NSCLC Drug Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Aug 2, 2019 Comparison of KRAS Liquid Biopsy Kits Confirms Differences at Low Mutant Allele Fraction Jun 6, 2019 TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts Premium May 29, 2019 CRISPR Framework Helps Identify Combination Therapies for Optimal Targeting of KRAS Mutant Feb 26, 2019 Thermo Fisher Scientific Oncomine Dx Target Test Gets Expanded Regulatory Approval in Japan Jan 29, 2019 AmoyDx, Sanomics Ink Deal for Multigene Mutation Detection Kit Oct 31, 2018 Lung Cancer Panel From PlexBio Receives CE Mark Oct 17, 2018 Thermo Fisher Scientific Gets CE-IVD Mark for NGS Cancer Test Sep 27, 2018 UK Group Develops Cancer Liquid Biopsy Assay to Detect Low-Level Mutations Premium Oct 17, 2017 AstraZeneca Publishes Head-to-Head Study of 13 KRAS Mutation Detection Technologies Premium Jan 6, 2017 Two Pore Guys Collaborating With UCSF on Point-of-Care Liquid Biopsy Dec 15, 2016 Biocartis Gets CE Mark for Idylla NRAS-BRAF Mutation Test Oct 3, 2016 KRAS-Driven Tumor Growth Inhibited by MicroRNA May 13, 2016 Colorectal Cancer Patients' Cetuximab Response Can Be Discerned From FCGR2A Genotype Premium Oct 27, 2015 Biocartis Granted $1.5M to Develop Liquid Biopsy Version of KRAS, BRAF Tests Jul 9, 2015 U of Toronto Study Demos Electrochemical Clamp Chip for Detection of Circulating Nucleic Acids Premium Jun 24, 2015 Biocartis' KRAS Mutation Test Receives CE-IVD Mark Load More Breaking News New Products Posted to GenomeWeb: Labcorp, Omniseq, Dovetail Genomics, DNA Script, More People in the News: New Appointments at Sema4, Strata Oncology, Bionano Genomics, More Co-Diagnostics Gets CE Mark for Saliva-Based Molecular SARS-CoV-2 Test Yourgene Health Awarded £232K Contract to Supply Oncology Genotyping Testing Kits to NHS Wales Qiagen to Distribute JADBio Life Science Analytics Platform BC Platforms Forms Data Management Alliance With Nonprofit CureDuchenne The Scan Billions for Antivirals The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports. NFT of the Web Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports. 23andMe on the Nasdaq 23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported. Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.